CHICAGO, April 18, 2025 /PRNewswire/ -- SparX Biopharmaceutical Corp. announced today that it will unveil significant clinical advancements regarding its lead therapeutic asset, SPX-303, a groundbreaking first-in-class anti-LILRB2/PD-L1 bispecific antibody. This presentation is scheduled for the Trial-in-Progress poster session at the highly anticipated 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 28, from 2:00 PM to 5:00 PM. Notably, this event coincides with the one-year anniversary of the initial patient dosing of this innovative bispecific antibody, which is currently part of a Phase 1 clinical trial.

The upcoming presentation will provide a detailed overview of SPX-303s unique dual mechanism of action, which targets both myeloid and T-cell immune checkpoints, a critical factor in the modulation of immune responses against tumors. This will be further elaborated upon during a Satellite Symposium titled Harnessing Super Immunotherapy and ADCs to Redefine the Standard of Care. The symposium is co-hosted by the esteemed University of Illinois at Chicago Cancer Center and Yao YuanAcademy for Pharma Innovation, and it will bring together a panel of expert clinicians, academic researchers, and industry leaders. Together, they will explore the potential of next-generation immuno-oncology therapies, often referred to as Super IO, in conjunction with antibody-drug conjugates (ADCs). This innovative strategy aims to merge the precise tumor-targeting capabilities of ADCs with the immune-activating strengths of checkpoint inhibitors, with the goal of achieving deeper and more sustainable anti-tumor responses.

SPX-303, as a pioneering bispecific antibody targeting LILRB2 and PD-L1, is currently in the process of enrolling patients diagnosed with resistant or refractory solid tumors at a dosing level of 20 mg/kg. Dr. Gui-Dong Zhu, the CEO of SparX, remarked, This innovative program represents a significant advancement in macrophage checkpoint blockade and T cell co-engagement strategies. It holds promise as a potential next-generation immuno-oncology therapyor 'Super IO' boosterfor patients with limited treatment options.

The SPX-303 poster will specifically be showcased at Poster #CT116-11 within the Phase I Clinical Trials in Progress session at McCormick Place, Chicago, on April 28, from 2:00 PM to 5:00 PM. Additionally, the Satellite Symposium is set to occur at the prestigious Trump International Hotel & Tower Chicago, located at 401 N Wabash Ave, Chicago, IL 60611. SparX encourages all attendees to visit its exhibition booth during the symposium and strongly urges early registration via the